DR REDDYS LABORATORIES LTD
corporate_fare Company Profile
DR REDDYS LABORATORIES LTD (NYSE:RDY) is a publicly traded company in the Life Sciences sector. Wiseek monitors RDY SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Annual Report Reveals 26% Profit Drop, North America Revenue Decline, and Key Regulatory Setbacks in China and US Biosimilars
- Dr. Reddy's Launches First Generic Semaglutide Injection in Canada
- Dr. Reddy's Reports Q4 & FY26 Results, Highlights Semaglutide Approvals & Strong Growth in Key Markets
- Dr. Reddy's Reports Sharp Q4 Profit Decline Amidst One-Off Charges; Full-Year Profit Down 24%
- Dr. Reddy's Strengthens Board with AI Expert, Elevates Key India Generics Head
Financial Snapshot
Insider Transactions
RDY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.